J Biomed Nanotechnol. 2020 Aug 1;16(8):1219-1228. doi: 10.1166/jbn.2020.2970.
The emerging of cancer immunotherapy is a great progress in cancer therapy. However, accumulating evidences have shown that tumor microenvironment (TME) exerted strong inhibition effects on cancer immunotherapy. In order to solve this issue, a cell membrane vehicle (CMV) was developed and employed to encapsulate both chlorins e6 (Ce6) and sorafenib (Sfn). The obtained drug delivery system (DDS, CMV/C-S was expected to enhance the immune response in cancer therapy by remodeling the TME. The results showed that CMV/C-S was highly stable under physiological environment with responsive drug release upon laser irradiations and high tumor targetability, which all contributed to promising anticancer performance / . Especially, the photodynamic nature of Ce6 could exert significant immunogenic cell death (ICD) to trigger immune response. At the same time, with the TME regulation effects of Sfn, the outcome of cancer immunotherapy was significantly enhanced as compare to mono-therapies. The study offers a novel approach for effective cancer immunotherapy.
癌症免疫疗法的出现是癌症治疗的一大进展。然而，越来越多的证据表明，肿瘤微环境（TME）对癌症免疫疗法具有很强的抑制作用。为了解决这个问题，开发了一种细胞膜载体（CMV），并将其用于封装氯仿 E6（Ce6）和索拉非尼（Sfn）。所得到的药物递送系统（DDS，CMV/C-S）有望通过重塑 TME 来增强癌症治疗中的免疫反应。结果表明，CMV/C-S 在生理环境下高度稳定，在激光照射下具有响应性药物释放和高肿瘤靶向性，这都有助于实现有前景的抗癌性能。特别是，Ce6 的光动力性质可以发挥显著的免疫原性细胞死亡（ICD）作用，引发免疫反应。同时，由于 Sfn 对 TME 的调节作用，与单一疗法相比，癌症免疫疗法的效果显著增强。该研究为有效的癌症免疫疗法提供了一种新的方法。
